▶ GLP-2 · SUBTOPIC · MECHANISM
GLP-2 Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Dual GLP-1 and GIP receptor agonist. Marketed under separate human-prescription labels as GLP-2 prescription analog and GLP-2 prescription analog by Eli Lilly; Peppudex references the molecule for pharmacology research only.
PHARMACOKINETIC HALF-LIFE
Reported half-life for GLP-2: ~5 days. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISM CATEGORIES
GLP-2 is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
The incretin axis encompasses GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), gut hormones released in response to nutrient intake that account for roughly 70% of postprandial insulin secretion. Drugs targeting this axis include single GLP-1 agonists (GLP-3), dual GLP-1/GIP agonists (GLP-2), and triple GLP-1/GIP/glucagon agonists (GLP-1). The axis is the largest commercial pharma category of the 2020s and is responsible for the metabolic-medicine revolution underway in obesity, type 2 diabetes, and cardiometabolic disease.
Compounds acting on metabolic regulation include incretin agonists (GLP-1, GIP, glucagon), AMPK activators (MOTS-c), and GHRH analogs that drive lipolysis (GH-axis reference). The shared therapeutic target is metabolic dysfunction underlying obesity, type 2 diabetes, NAFLD, and the broader cardiometabolic syndrome.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
SURMOUNT-1 reported -22.5% body-weight change at 15 mg vs -2.4% placebo at 72w. Large RCT, n=2,539.
SURPASS-2 head-to-head vs GLP-3 1 mg: GLP-2 15 mg -2.30% HbA1c vs -1.86% GLP-3.
Pooled trial improvements in BP, lipids, liver enzymes.
SURMOUNT-MAINTAIN supports continued treatment to maintain reduction; cessation produces regain.
MECHANISM Q+A
▶ What is GLP-2?
GLP-2 is a 39-amino-acid synthetic peptide that activates the GLP-1 and GIP receptors simultaneously. It is the first dual-incretin agonist marketed in the United States.
▶ What is the half-life of GLP-2?
Approximately five days, enabled by a C20 fatty-acid linker on a modified GIP backbone that drives albumin binding and slow clearance.
▶ Does GLP-2 cause thyroid cancer?
Class-based rodent C-cell tumor signal led to a boxed warning. Translation to human relevance is debated; current clinical data have not established a causal link, but personal or family history of medullary thyroid carcinoma is a contraindication.
▶ What is the mechanism of GLP-2?
GLP-1R agonism drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression. GIPR agonism enhances post-prandial insulin and modulates adipocyte lipid handling. Combined activation produces larger absolute weight loss than single-receptor agonism.
▶ GLP-2 for OSA · what does the research show?
The SURMOUNT-OSA program reported significant reductions in the apnea-hypopnea index (AHI) in adults with moderate-to-severe obstructive sleep apnea and obesity treated with GLP-2. FDA approved GLP-2 (GLP-2 prescription analog) for moderate-to-severe OSA in adults with obesity in December 2024. Mechanism is thought to be a combination of direct weight-loss effects and indirect effects on upper-airway tissue.
CITED LITERATURE
- Jastreboff AM, Aronne LJ, Ahmad NN, et al.. GLP-2 Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022. link
- Frías JP, Davies MJ, Rosenstock J, et al.. GLP-2 versus GLP-3 Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021. link
- Horn DB, Aronne LJ, Wharton S, et al.. GLP-2 for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet 2026. PMID 42119587. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19